Tid 29 Mars 2011 – 31 Mars 2011
Plats Marina Sands Convention Centre, Singapore.
Potent and consistent antiviral efficacy was demonstrated at 24-week end-of-treatment and in interim SVR4 and SVR12 results. There were no clinically relevant differences between TMC435 treatment groups and placebo for adverse events.
GlaxoSmithKline (GSK) and Medivir (STO: MVIR-B) today announced an exclusive agreement for the commercialization of cold sore treatment, Xerclear™ (acyclovir and hydrocortisone) for non-prescription use (OTC) in key global markets. Xerclear™ is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing.
Forsknings- och högskoleminister Tobias Krantz delade ut priset till Medivirs vd Ron Long vid en ceremoni på SwedenBIOs årsmöte i Stockholm. Medivir tilldelas priset för alla de framgångar bolaget uppnått under 2009.